Figure 6 | Scientific Reports

Figure 6

From: A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid

Figure 6

Effects of Intralipid treatment on the tumor growth and the anti-tumor efficacy of DACHPt/HANP as well as the survival rate in a HT-29 xenograft tumor model. (A) Treatment protocol. (B) Survival rate of HT-29 bearing BALB/c nude mice for the four treatment groups. (C) Changes of the tumor size upon treatment with vehicle, Intralipid alone, and DACHPt/HANP at 2 mg Pt/kg with or without Intralipid administration. H&E staining of the bone marrow is shown in (DK). (D,E) DACHPt/HANP treatment, with no Intralipid, causes moderate/severe depletion of erythroid and myeloid precursor cells in the bone marrow. (F,G) Intralipid treatment significantly reduces this damage. (H,I) and (J,K) Bone marrow from (i) vehicle-treated, and (ii) Intralipid alone group.

Back to article page